Voglibose 0.2 mg, Glimepiride 3 mg & Metformin Hydrochloride 500 mg GLIMITERIS TRIO 0.2 Voglibose: Class: Voglibose is an alpha-glucosidase inhibitor. Mechanism of Action: It works by delaying the digestion and absorption of carbohydrates in the intestines. This results in a slower and more gradual increase in blood sugar levels following meals. Usage: Voglibose is especially effective in controlling postprandial (after meal) blood glucose spikes. Glimepiride: Class: Glimepiride belongs to the sulfonylurea class of drugs. Mechanism of Action: It stimulates the pancreas to produce more insulin, a hormone that lowers blood glucose levels. It also helps the body use insulin more efficiently. Usage: It's used to improve blood glucose control in adults with Type 2 diabetes. Side Effects: The primary side effect of concern is hypoglycemia (low blood sugar levels), particularly if a meal is missed or delayed. Metformin Hydrochloride: Class: Metformin is a biguanide. Mechanism of Action: It works by decreasing glucose production in the liver and improving insulin sensitivity, which helps the body use its own insulin more effectively. Usage: Often used as a first-line treatment for Type 2 diabetes, metformin is particularly effective in overweight or obese individuals. Side Effects: Common side effects include gastrointestinal disturbances, but it rarely causes hypoglycemia when used alone. GLIMITERIS TRIO 0.2 can provide a more comprehensive approach to managing blood sugar levels, as they target different aspects of diabetes control: Voglibose reduces the rapid increase in blood sugar after meals. Glimepiride increases insulin production. Metformin improves insulin sensitivity and reduces the amount of glucose produced by the liver. GLIMITERIS TRIO 0.2 needs to be managed carefully: Monitoring Blood Sugar Levels: Regular monitoring is essential to adjust dosages and avoid hypoglycemia or hyperglycemia. Diet and Exercise: Effective diabetes management also includes diet modification, regular physical activity, and weight management. Awareness of Side Effects: Patients should be informed about the potential side effects of each medication, including the signs of hypoglycemia. Steris Healthcare Pvt. Ltd. is a Leading Pharmaceutical Company in India. Established in the year of May 2018. We have 750+ Products & 16+ Super Specialty Segments. Every week we have a new product in our portfolio. In Last 5 years we are dealing in Chronic Therapy and in 5 years we grow by 200% Annually, because we deal in high quality medicine. Steris medicine manufactures at WHO-GMP Approved Plants & We have Legal manufacturing contracts with all leading manufacturers of India. Today we have 1000+ Business Franchise Partners in PAN India. Steris's medicine supply in India's Top or Reputed Hospitals, Pharmacy, Government use or Railway use. Grow with a similar pace with the STERIS. Be first to launch like us. For further information please contact: info@sterispharma.com order now: https://www.sterisonline.com/product/glimiteris-trio-0-2-134376